Fortrea (FTRE) Set to Post Earnings on Thursday

Fortrea (NASDAQ:FTRE) will likely be posting its Q3 2026 results before the market opens on Thursday, October 29th. Analysts expect Fortrea to announce earnings of $0.2172 per share and revenue of $671.57 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, October 29, 2026 at 8:00 AM ET.

Fortrea (NASDAQ:FTRE) last posted its earnings results on Wednesday, July 29th. The company reported $0.23 EPS for the quarter, beating analysts’ consensus estimates of $0.18 by $0.05. Fortrea had a positive return on equity of 10.72% and a negative net margin of 3.18%. The firm had revenue of $678.20 million during the quarter, compared to the consensus estimate of $647.57 million. On average, analysts expect Fortrea to post $0.86 EPS for the current fiscal year and $1.04 EPS for the next fiscal year.

Fortrea Trading Up 0.8%

FTRE stock opened at $23.83 on Tuesday. The firm has a fifty day moving average price of $19.82 and a 200 day moving average price of $15.62. Fortrea has a fifty-two week low of $8.55 and a fifty-two week high of $24.83. The firm has a market cap of $2.27 billion, a PE ratio of -26.19, a price-to-earnings-growth ratio of 0.57 and a beta of 1.93. The company has a debt-to-equity ratio of 1.98, a quick ratio of 0.96 and a current ratio of 0.96.

Analysts Set New Price Targets

FTRE has been the subject of a number of recent research reports. Evercore reissued an “outperform” rating on shares of Fortrea in a research note on Wednesday, July 29th. TD Cowen upped their target price on shares of Fortrea from $19.00 to $23.00 and gave the company a “buy” rating in a research report on Tuesday, August 4th. Weiss Ratings restated a “sell (d-)” rating on shares of Fortrea in a research report on Thursday, October 15th. Deutsche Bank Aktiengesellschaft raised shares of Fortrea from a “hold” rating to a “buy” rating and increased their price target for the company from $20.00 to $25.00 in a report on Thursday, October 15th. Finally, Wall Street Zen upgraded Fortrea from a “hold” rating to a “buy” rating in a research report on Saturday, October 10th. Seven equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Fortrea currently has an average rating of “Hold” and an average price target of $22.80.

Insiders Place Their Bets

In related news, CEO Anshul Thakral sold 99,869 shares of the stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $19.16, for a total transaction of $1,913,490.04. Following the sale, the chief executive officer owned 316,797 shares in the company, valued at approximately $6,069,830.52. This represents a 23.97% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 0.73% of the company’s stock.

Fortrea Company Profile

Fortrea Holdings Inc is a global contract research organization (CRO) that provides services to pharmaceutical, biotechnology and medical device companies. The company helps clients plan, manage and execute clinical development programs, supporting the testing of new medicines and therapies from early-stage research through regulatory approval and post-approval activities.

Its services include Phase I through Phase IV clinical trials, clinical operations, patient recruitment and access, data management, biostatistics, medical monitoring, pharmacovigilance and regulatory support.